{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:56:54Z","timestamp":1787025414688,"version":"build-2736575974"},"reference-count":27,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"abstract":"\n Background<\/jats:title>\n In psoriasis patients treated with biologics, some achieve an ideal response to biologics and remain clear of lesions for several months, even years (super-responders-SRs), whereas others repeatedly fail to respond (super-non-responders-SNRs) to the biologic.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate the clinical characteristics of SRs and SNRs in psoriasis patients treated with biologic interleukin-17 inhibitors.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Chronic plaque psoriasis or psoriasis vulgaris patients who received IL-17i treatment for more than 6 months were included.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n In total, 664 patients were included, with 120 (18.63%) categorised as SRs and 82 (12.73%) as SNRs. Compared to SNRs, SRs were mostly female, had lower body weight and BMI, and were less likely to have received previous systemic treatment. Lower weight and BMI and the absence of previous treatment may serve as predictors of SRs. Compared to controls, the SNRs had higher body weight and BMI, longer disease duration, were more likely to have received previous systemic treatment, and had a greater number of comorbidities. Higher BMI, longer disease duration, the presence of previous treatment, and abnormal C-reactive protein (CRP) value serve as predictors of SNRs.<\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n Single-centre study has a relatively small size.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Lower BMI and the absence of previous treatment may serve as predictors of SRs. In contrast, higher BMI, longer disease duration, the presence of previous treatment, and abnormal CRP value may serve as predictors of SNRs.<\/jats:p>\n <\/jats:sec>","DOI":"10.25259\/ijdvl_32_2025","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T06:59:43Z","timestamp":1756882783000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical characterisation of super-responders and super-non-responders in psoriasis patients treated with interleukin-17 inhibitors: A real-world study"],"prefix":"10.25259","volume":"0","author":[{"given":"Lihong","family":"Zhang","sequence":"first","affiliation":[{"name":"Hospital for Skin Diseases, Shandong First Medical University, Zhangzhuang, Jinan, Shandong, China"},{"name":"Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Zhangzhuang, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanqing","family":"Geng","sequence":"additional","affiliation":[{"name":"Hospital for Skin Diseases, Shandong First Medical University, Zhangzhuang, Jinan, Shandong, China"},{"name":"Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Zhangzhuang, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Li","sequence":"additional","affiliation":[{"name":"Hospital for Skin Diseases, Shandong First Medical University, Zhangzhuang, Jinan, Shandong, China"},{"name":"Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Zhangzhuang, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[{"name":"Hospital for Skin Diseases, Shandong First Medical University, Zhangzhuang, Jinan, Shandong, China"},{"name":"Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Zhangzhuang, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"10.25259\/IJDVL_32_2025\/ref-1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_32_2025\/ref-2","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/jdv.13854","article-title":"A systematic review of worldwide epidemiology of psoriasis","volume":"31","author":"Michalek","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_32_2025\/ref-3","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_32_2025\/ref-4","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_32_2025\/ref-5","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_32_2025\/ref-6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/bjd\/ljad446","article-title":"Characteristics of \u2018super responders\u2019 and \u2018super nonresponders\u2019 to first biologic monotherapy for psoriasis: A nested case\u2013control study","volume":"190","author":"Mason","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_32_2025\/ref-7","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/jdv.18126","article-title":"Prevalence and characterization of treatment\u2010refractory psoriasis and super\u2010responders to biologic treatment: A nationwide study","volume":"36","author":"Loft","year":"2022","journal-title":"Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_32_2025\/ref-8","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1111\/jdv.15659","article-title":"High-resolution HLA typing identifies a new \u2018super responder\u2019 subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02\/HLA-C*04, in response to ustekinumab","volume":"33","author":"Talamonti","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_32_2025\/ref-9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s40291-016-0199-y","article-title":"HLA-c*18:01: A rare allele in the European Caucasian population coinciding with difficult-to-treat plaque psoriasis","volume":"20","author":"Galluzzo","year":"2016","journal-title":"Mol Diagn Ther"},{"key":"10.25259\/IJDVL_32_2025\/ref-10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jaad.2021.06.883","article-title":"Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in corrona psoriasis registry","volume":"86","author":"Enos","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_32_2025\/ref-11","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s40261-023-01280-9","article-title":"Real-world performance of a new strategy for off-label use of guselkumab in moderate to severe psoriasis: Super-responder patients as the epitome of efficacy and optimisation","volume":"43","author":"Herranz-Pinto","year":"2023","journal-title":"Clin Drug Investig"},{"key":"10.25259\/IJDVL_32_2025\/ref-12","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3390\/life12091412","article-title":"Super-responders in moderate-severe psoriasis under guselkumab treatment: Myths, realities and future perspectives","volume":"12","author":"Ruiz-Villaverde","year":"2022","journal-title":"Life (Basel)"},{"key":"10.25259\/IJDVL_32_2025\/ref-13","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/ijd.15784","article-title":"Super responders to guselkumab treatment in moderate\u2010to\u2010severe psoriasis: A real clinical practice pilot series","volume":"61","author":"Ruiz\u2010Villaverde","year":"2022","journal-title":"Int J Dermatology"},{"key":"10.25259\/IJDVL_32_2025\/ref-14","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1111\/jdv.18474","article-title":"Super\u2010response to guselkumab treatment in patients with moderate\u2010to\u2010severe psoriasis: age, body weight, baseline psoriasis area and severity index and baseline investigator\u2019s global assessment scores predict complete skin clearance","volume":"36","author":"Reich","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_32_2025\/ref-15","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1111\/jdv.19236","article-title":"Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (\u2018clinical super response\u2019): Week 28 results from the ongoing phase IIIb randomized, double\u2010blind, parallel\u2010group, GUIDE study: An analysis with considerations for future studies","volume":"37","author":"Sch\u00e4kel","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_32_2025\/ref-16","doi-asserted-by":"crossref","first-page":"AB195","DOI":"10.1016\/j.jaad.2022.06.813","article-title":"33830 Prognostic factors for early PASI 100 response in psoriasis patients treated with guselkumab: Results from the GUIDE study","volume":"87","author":"Sch\u00e4kel","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_32_2025\/ref-17","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1111\/exd.14731","article-title":"\u201cSuperresponders\u201d at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors","volume":"32","author":"Mastorino","year":"2023","journal-title":"Exp Dermatol"},{"key":"10.25259\/IJDVL_32_2025\/ref-18","article-title":"Super\u2010responders in psoriasis under interleukin 23 inhibitor treatments, experience in two centres","volume":"37","author":"Men\u00e9ndez S\u00e1nchez","year":"2023","journal-title":"Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_32_2025\/ref-19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/bjd.17756","article-title":"Long\u2010term, real\u2010world efficacy of biologics for psoriasis: A single centre\u2019s experience","volume":"181","author":"Mercieca","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_32_2025\/ref-20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1146\/annurev-immunol-101320-125133","article-title":"Sex Differences in Immunity","volume":"40","author":"Wilkinson","year":"2022","journal-title":"Annu Rev Immunol"},{"key":"10.25259\/IJDVL_32_2025\/ref-21","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/jdv.14802","article-title":"A multicenter, prospective, observational study examining the impact of risk factors, such as BMI and waist circumference, on quality of life improvement and clinical response in moderate\u2010to\u2010severe plaque\u2010type psoriasis patients treated with infliximab in routine care settings of Greece","volume":"32","author":"Petridis","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_32_2025\/ref-22","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1517\/14712598.2014.900541","article-title":"The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: A randomized controlled prospective trial","volume":"14","author":"Al-Mutairi","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"10.25259\/IJDVL_32_2025\/ref-23","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/jdv.18825","article-title":"Brodalumab in plaque psoriasis: Real\u2010world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104 weeks","volume":"37","author":"Rompoti","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_32_2025\/ref-24","doi-asserted-by":"publisher","first-page":"2331782","DOI":"10.1080\/09546634.2024.2331782","article-title":"Comparison between super-responders and non-super-responders in psoriasis under adalimumab treatment: A real-life cohort study on the effectiveness and drug survival over one-year","volume":"35","author":"Liu","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"10.25259\/IJDVL_32_2025\/ref-25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s00403-024-02994-2","article-title":"Associations of novel complete blood count-derived inflammatory markers with psoriasis: A systematic review and meta-analysis","volume":"316","author":"Liu","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"10.25259\/IJDVL_32_2025\/ref-26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00403-024-02823-6","article-title":"Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in psoriasis: A systematic review and meta-analysis","volume":"316","author":"Ye","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"10.25259\/IJDVL_32_2025\/ref-27","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1111\/1346-8138.13875","article-title":"Neutrophil\u2013lymphocyte ratio, platelet\u2013lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: Response to therapy with biologics","volume":"44","author":"Asahina","year":"2017","journal-title":"J Dermatol"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/clinical-characterisation-of-super-responders-and-super-non-responders-in-psoriasis-patients-treated-with-interleukin-17-inhibitors-a-real-world-study\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/clinical-characterisation-of-super-responders-and-super-non-responders-in-psoriasis-patients-treated-with-interleukin-17-inhibitors-a-real-world-study\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T06:59:44Z","timestamp":1756882784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/clinical-characterisation-of-super-responders-and-super-non-responders-in-psoriasis-patients-treated-with-interleukin-17-inhibitors-a-real-world-study\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":27,"alternative-id":["10.25259\/IJDVL_32_2025"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_32_2025","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"article-number":"1"}}